Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety
Pooled result · Total MIResult — go to the resultRelative risk 0.86Authors' conclusion
GLP-1RA reduced the risk of MI, stroke, cardiovascular mortality and MACE in a broad range of patients with and without T2DM and/or prior ASCVD, supporting its role in ASCVD prevention, especially in the cohort with high BMI.
Study context
- Population
- Patients with and without T2D and/or prior atherosclerotic cardiovascular disease (ASCVD) in randomised trials (Medline and Embase, inception to 29 May 2025)
- Participants
- 109,846 patients25 studies
- Comparison
- GLP-1 RA vs placebo
- Outcome
- MI
- Follow-up
- 3.48 ± 1.51 (1.55 to 5.47) years
Methodological detailspairwise meta-analysis, random-effects model
- Pairwise meta-analysis
- Random-effects model
Pooled result
Total MI
Relative risk
0.86
P < 0.01
As reported in the abstract
- Number needed to benefit (numbers needed to benefit (NNTB)) to prevent one myocardial infarction (MI)
- 207
Further pooled results
| Outcome | RR | P value |
|---|---|---|
| Cardiovascular mortalityNNTB 170 | 0.87 | P < 0.01 |
| MACENNTB 67 | 0.87 | P < 0.01 |
| StrokeNNTB 335 | 0.88 | P < 0.01 |
MI risk reduction by BMI (meta-regression)
- Higher BMI associated with greater MI risk reduction in GLP-1RA users (β)
- −0.09, p = 0.03
Safety
| Outcome | RR | P value |
|---|---|---|
| Gastrointestinal side-effectsNNTH 9 | 1.55 | P < 0.01 |
Original publication
Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety. Cardiovasc Diabetol. Published 12 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →